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Abstract
Type 2 Diabetes Mellitus (Type 2 DM) is a metabolic disorder group with mechanisms that include hyperglycemia, 
insulin resistance and hyperinsulinemia. Type 2 DM has a close association with IGF-1, where the active form of 
the IGF-1 becomes elevated by reason of the fact that hyperinsulinemia inhibits the production of IGF-binding 
proteins (IGFBP) 1/IGFBP 2. The active form of IGF-1 has the ability to promote cell proliferation and inhibit 
apoptosis, hence becomes one of the risk factors for cancer cell growth. This was an analytical study conducted 
in August at the Harapan Bunda Clinic, Medan, Indonesia to determine the difference between the IGF-1 level and 
blood glucose level in type 2 DM patients in different age groups. Twenty subjects with Type 2 DM participated 
in this study and were divided based on their age into 35–50 years old or Group 1 (n=10) and 51–65 year old 
group or Group 2 (n=10). The IGF-1 levels in both groups were compared and analyzed using the T-test dependent 
method. Results showed that the IGF-1 and blood glucose levels were higher in Group 1 (35-50 years old) when 
compared to Group 2 and the difference was significant. The change in the IGF-1 level in diabetic patients cannot 
be determined only by the blood sugar level.
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Kadar IGF-1 pada Pasien dengan Diabetes Melitus Tipe 2 
Abstrak 
Diabetes Melitus Tipe 2 (DM Tipe 2) merupakan suatu kelompok gangguan metabolik dengan mekanisme 
penyebab seperti hiperglikemia, resistensi insulin dan hiperinsulinemia. DM tipe 2 memiliki kaitan yang erat 
dengan IGF-1, bentuk aktif IGF-1 meningkat karena fakta bahwa hiperinsulinemia menghambat produksi 
protein pengikat IGF (IGFBP) 1/IGFBP 2. Kemampuan yang dimiliki bentuk aktif IGF-1 dalam hal proliferasi sel 
dan menghambat apoptosis sehingga menjadi salah satu faktor resiko pertumbuhan sel kanker. Penelitian ini 
dilakukan pada bulan Agustus di Klinik Harapan Bunda Medan untuk menentukan perbedaan kadar IGF-1 dengan 
kadar glukosa darah pada pasien DM tipe 2 berdasarkan kelompok umur yang berbeda. Penelitian menggunakan 
20 sampel pasien DM tipe 2 yang dibagi dalam 2 kelompok, dimana 10 sampel berusia 35–50 tahun (kelompok 
1), dan 10 sampel berusia 51–65 tahun (kelompok 2). Desain penelitian yang digunakan adalah penelitian analitik 
yang membandingkan kadar IGF-1 pada dua kelompok umur yang berbeda. Hasil penelitian dianalisis dengan 
metode t-test dependent dan didapati bahwa kadar IGF-1 pada kelompok umur 35–50 tahun (kelompok 1) lebih 
tinggi daripada kelompok umur 51–65 tahun (kelompok 2). Simpulan, terdapat perbedaan yang signifikan pada 
kadar IGF-1 kelompok umur 1 dan 2. Naik-turunnya kadar IGF-1 pada kedua kelompok umur pasien DM tipe 2 
tidak hanya dapat ditentukan oleh kadar gula darah.
Kata kunci: Diabetes melitus tipe 2, kadar IGF-1, kadar glukosa darah
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Introduction
Type 2 Diabetes Mellitus (type 2 DM) is one of 
the major health problems. In the  Diabetes Atlas 
2019 (International Diabetes Federation), it was 
noted that sufferers of type 2 diabetes in the 
world in 2019 amounted to 463 million people 
and that number will continue to increase and is 
estimated in 2045 to be 629 million people. The 
disease ranks seventh in terms of death-related 
diseases in developing countries and Indonesia 
ranks sixth out of 10 developing countries 
with the highest number of people with type 
2 diabetes.1 Estimates from the World Health 
Organization (WHO), an increase in the number 
of people with type 2 DM in Indonesia from 8.4 
million in 2000 to around 21.3 million in 2030. 
This report shows an increase in the number of 
people with type 2 DM by 2–3 fold in 2035.2 
Type 2 DM is closely related to IGF-1, where 
the active form of IGF-1 is increased due to 
the fact that hyperinsulinemia inhibits the 
production of IGF-binding protein (IGFBP) 1 / 
IGFBP 2. The ability of the active form of IGF-
1 along with its receptors is stronger in terms 
of proliferation cells and inhibits apoptosis. 
Therefore, the risk of cancer cell growth more 
easily occur. A study from the National Center for 
Biotechnology Information 2010 found that low 
serum IGF-1 was positively related to Diabetes 
Mellitus in younger subjects, then high IGF-1 
serum was associated with older subjects.3,4 The 
study is in line with the journal from Joel Furman 
which states that a high serum IGF-1 is seen with 
age.5
Based on the study from Swapnil and his 
team also found the fact that in addition to IGF-
1, there is also IGFBP-1/Insulin Growth Factor 
Binding Protein-1 plays an important role in 
type 2 DM. High IGFBP-1 has been shown to 
cause a decrease in IGF-1 and circulating glucose 
levels which means IGFBP-1 is a component of 
IGF-1 regulation.6 Along with age, insulin which 
that contribute to IGFBP-1 and IGF-1 regulation 
can be disrupted and cause unstable effects on 
IGFBP-1 production.7 
Age and Diabetes Mellitus have a bond. A 
study showed that IGF-1 serum level increases 
in children with age, reaching its peak during 
puberty, followed by a subsequent decline in 
adulthood. A similar pattern with age has been 
found in individuals with diabetes.8 Patient with 
Diabetes Mellitus also decreased functional 
status and loss of muscle mass increasing with 
age. All of these things have a major impact on 
the ability to manage diabetes independently, 
thus making Diabetes Melitus increasingly out 
of control. As a result, strategies to improve 
management in older adults are chosen. The 
risk of overtreatment of hyperglycemia in older 
adults also can cause hypoglycemia.9 Therefore, 
this study was designed to evaluate the total 
serum levels of IGF-I in type 2 diabetic patients 
aged 35–65 years.
Methods
This research is analytic cross sectional that 
to assess the correlation of IGF-1 levels in two 
different age groups of type 2 Diabetes Mellitus 
patients, conducted in August 2019 at Harapan 
Bunda Clinic, Medan, Indonesia. It approved by 
Ethic Committee (020/KEPK/UNPRI/XI/2020). 
Inclusion criteria were controlled type 2 Diabetes 
Mellitus patient, female or male, aged 35–65 
years, and willing to participate in the study. 
While the exclusion criteria are type 2 diabetes 
mellitus patients with other comorbidities. 
Sampling was done incidentally from patients 
who met the criteria for acceptance of the sample 
until the number of samples were met, as many 
as 20 samples. Anamnesis is performed on type 
2 diabetes mellitus patients at Harapan Bunda 
Clinic. Then the patient is given information for 
informed consent about the study. If the patient 
agrees and has signed an informed consent. 
Venous blood sampling is carried out in the 
morning from 8–9 after the patient is fasting 
for 10–12 hours. Blood samples were put in an 
edta vacutainer, centrifuged, and then examined 
fasting blood sugar levels and IGF-1 levels in 
the Indonesian Laboratory (PATHLAB) Medan. 
The results of the examination of fasting blood 
sugar levels and IGF-1 levels are recorded on the 
data collection sheet and then carried out data 
processing according to age group.
All statistical analyzes were performed using 
SPSS version 17.0. The limit of significance test 
(p) used in this study was 0.05. To determine the 
normality of data distribution, the Kolmogorov-
Smirnov test was used. Data that have a normal 
distribution, to assess differences in the mean 
of two variables that are numerically used 
t-independent test. To assess the relationship 
between the independent variable and the 
dependent variable used correlation test. The 
independent t-test was used to differentiate the 
glucose and IGF-1 levels among two groups and 
the Pearson correlation test was used to analyze 
the correlation between IGF-1 and glucose levels.
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Results 
The subjects of this study were 20 women with 
type 2 diabetes mellitus, where there were more 
people at the age of 46–50 years as many as 14 of 
20 people and the remaining 6 of 20 people aged 
40–45 years (Table 1).
Comparison of fasting blood sugar levels of 
patients with type 2 diabetes mellitus against 
age groups there was no statistically significant 
difference (p=0.219; Tabel 2). The average blood 
sugar level of subjects from the age group of 35-
50 years was 177.0±29.70 and 176.1±53.15 from 
the older age group (51–65 years).
Table 3 shows the statistically significant 
differences between IGF-1 levels in the two age 
groups (p=0.047). Where the average IGF-1 level 
of subjects from the age group of 35–50 years 
(140.60±16.91) is higher than the age group 51–
65 years (126.50±42.76).
After knowing the effect of age on blood 
sugar levels and IGF-1 subjects, then the analysis 
continued with the correlation analysis between 
blood sugar levels and IGF-1 levels of subjects. 
There were no statistically significant correlation 
between blood sugar level (176.55±41.91) and 
IGF-1 level (133.55±32.46) on the whole subject 
Table 3 IGF-1 Level in the Age Group of Type 
 2 DM Patient
Age 
(years)
Level of IGF-1 (ng/mL)
[Mean ± SD] p-value
35–50 140.60 ± 16.91
0.047
51–65 126.50 ± 42.76







Table 2 Blood Sugar Level of Age Group of    
  Type 2 DM Patient
Age (years)




35–50 177.0 ± 29.70
0.219
51–65 176.1 ± 53.15
of the research, which is reflected in the value 
of p=0.209. Although the correlation coefficient 
is 0.293 which means that there is a very weak 
correlation between blood sugar level and IGF-
1 level, but the correlation is not statistically 
significant because the P value >0.05.
Discussion
Rony, in his research at RSUP Adam Malik Medan 
which obtained the proportion of patients with 
type 2 DM more women (51%) compared to 
men (49%).10 This is consistent with research 
that has been done in table 1 shows the type 
2 diabetes mellitus patients are more women 
(70%) than men (30%). Similar to the theory is 
that women are more at risk for type 2 diabetes 
because they have a greater chance of increasing 
their BMI (Body Mass Index). Monthly cycle 
syndrome (premenstrual syndrome) or post 
menopause that can make body fat distribution 
easily accumulate can also increase the risk of 
women suffering from type 2 diabetes.11 
In addition to gender, according Liyanage., 
age is not the only reason for the increase in 
type 2 diabetes because it contributes indirectly 
to the glucose tolerance. Direct contribution 
depends on BMI and physical activity. This is 
consistent with the theory which says that as 
we age, muscle mass decreases universally. 
This condition results in loss of muscle strength 
and an indirect contribution to the inability of 
individuals to carry out daily tasks. Reduced 
muscle mass and reduced physical activity that 
contribute to increased body fat and insulin 
resistance make individuals become obese. The 
presence of obesity changes the levels of plasma 
glucose, insulin and glucagon. Because of this, the 
development of insulin resistance and diabetes 
is more caused by changes in body composition 
than aging.12 This theory is also related to the 
results of the study in table 2 which shows no 
significant difference in blood sugar levels of the 
two age groups.
Insulin like Growth Factor-1 (IGF-1) has a 
close relationship with type 2 DM. In the case 
of type 2 DM, the IGF-1 component has an 
important role. It was found that the young age 
group (35–50 years) had higher levels of IGF-1, 
which is higher than the old age group (51–65 
years). The results of this study were not in line 
with the study of Garg et al. which obtained 
results that were inversely proportional to this 
study.3 However, these results are in accordance 
with research conducted by Gong et al., which 
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states that decreasing IGF-1 levels is associated 
with osteoporosis in old age. IGF-1 levels have 
decreased associated with the development of 
lean bones/slender bones. This characteristic 
of slender bones develops at an early age of 
puberty and lasts up to 52 weeks, which affects 
most bone growth. This condition causes an 
effect on the peak bone mass resulting in IGF-1 
need to provide a role as a protective and more 
optimal repair, and when bone loss becomes 
more common where there is a decrease in IGF-
1.13 
Rising and decreasing of IGF-1 can not only 
be determined by blood sugar levels. According 
to a study conducted by Clemmons, the variable 
that also regulates IGF-1 levels is nutrient intake. 
Either calorie or protein intake is an important 
variable. If calorie intake is reduced by about 
50%, there is a significant reduction in IGF-1 
secretion. The effects of protein are more graded 
so that even a small reduction results in changes 
in IGF-1. For every 25% reduction in protein 
intake, there is also an equivalent reduction in 
IGF-1. The majority of IGF-1 comes from liver 
synthesis. Both protein and calories participate 
in the regulation of liver synthesis with calories 
that regulate IGF-1 transcription and proteins 
that function primarily to regulate stability 
and translation.14,15 The results of IGF-1 usually 
cause changes and the results are inversely 
proportional to IGFBP in type 2 DM, so that the 
active form of IGF-1 also undergoes changes. In 
pre-diabetes, IGFBP-1 is initially lower. This is 
caused by hyperinsulinemia which occurs in the 
pre-diabetes phase. This condition results in an 
increase in the active form of IGF-1, but as insulin 
resistance develops, production of IGFBP-1 is 
inhibited and causes an active form of IGF-1 to 
increase. 
In reducing IGF-1 levels, a combination of 
good nutrition and physical activity is needed. 
Physical activity can avoid obesity which can 
cause changes in IGF-1 secretion.16,17 Without 
balance in lifestyle, it is possible for IGF-1 levels 
to increase. Elevated levels of IGF-1 are always 
associated with cancer risk, such as breast, 
prostate and colorectal cancer.18,19,20,21 Some 
of these studies further support the results 
achieved in this study that there is no close 
relationship between blood sugar levels with a 
decrease or increase in IGF-1.
Correlation between age and IGF-1 in patients 
with type 2 Diabetes Mellitus in Harapan Bunda 
Clinic Medan has been conducted with the 
following conclusions; there were no statistically 
significant differences in blood sugar levels in 
the age group; average IGF-1 levels in the age 
group (35–50 years) are higher than the age 
group (51–65 years); rising and decreasing of 
IGF-1 levels in each age group cannot only be 
determined by blood sugar level; and there is no 
close relationship between type 2 diabetes and 
IGF-1 levels.
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